Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TBI
TBI logo

TBI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy TrueBlue Inc (TBI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.700
1 Day change
-1.03%
52 Week Range
7.780
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

TrueBlue Inc (TBI) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are neutral to slightly bearish, options sentiment is skewed negatively, and there are no significant positive catalysts or financial data to support a buy decision. Holding or exploring other opportunities may be more prudent.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 50.288, suggesting no clear trend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the price is below the pivot level of 6.776, with key support at 6.462 and resistance at 7.089. Overall, the technical indicators are mixed, leaning slightly bearish.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Option Volume Put-Call Ratio indicates bearish sentiment, with significantly more puts being traded than calls. Implied volatility is extremely high (418.77), suggesting elevated uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • Bullish moving averages (SMA_5 > SMA_20 > SMA_200).

Neutral/Negative Catalysts

  • and a bearish options sentiment (Option Volume Put-Call Ratio=10.0). MACD is negative and expanding, and the stock has a 60% chance of a -1.26% decline in the next day.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast TBI stock price to fall
1 Analyst Rating
Wall Street analysts forecast TBI stock price to fall
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.770
sliders
Low
6
Averages
6
High
6
Current: 6.770
sliders
Low
6
Averages
6
High
6
Baird
Outperform
to
NULL
downgrade
$7
AI Analysis
2026-02-19
Reason
Baird
Price Target
$7
AI Analysis
2026-02-19
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on TrueBlue to $5.50 from $7 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results and Q1 outlook.
BMO Capital
Outperform
to
NULL
downgrade
$8 -> $6
2025-11-05
Reason
BMO Capital
Price Target
$8 -> $6
2025-11-05
downgrade
Outperform
to
NULL
Reason
BMO Capital lowered the firm's price target on TrueBlue to $6 from $8 and keeps an Outperform rating on the shares. The company delivered a sizable margin-driven and organic-growth driven beat to consensus, and while many staffing names have been under pressure, TrueBlue seemed to fare better this quarter, the analyst tells investors in a research note. BMO adds it is cautiously optimistic that this "Canary in the Coal mine" will continue to inflect positively as conditions continue to stabilize within its end markets.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TBI
Unlock Now

People Also Watch